arGEN-X and LEO Pharma sign deal to develop antibody-based treatments for skin conditions

Published: 21-May-2015
Research & Development

Dutch biotechnology company could potentially receive nearly €105m in payments


Dutch biotech arGEN-X and global Danish healthcare company LEO Pharma have formed an alliance in which they will jointly develop antibody-based drugs for the treatment of chronic inflammation underlying many skin conditions.

Under the terms of the agreement LEO Pharma receives exclusive access to an arGEN-X antibody currently in preclinical development for such skin conditions. arGEN-X also receives pre-IND payments of €4.5m, including an upfront payment and will also receive clinical, regulatory, and sales milestone payments potentially worth €100m, plus tiered royalties.

The companies will co-fund product development costs up to clinical trial application (CTA) filing. Additional terms and financial details were not disclosed.

Tim Van Hauwermeiren, Chief Executive of arGEN-X said: 'We see huge potential in this new partnership in harnessing the complementary expertise of both companies: arGEN-X’s advanced knowledge and capabilities in therapeutic antibody development and LEO Pharma’s global expertise in bringing products to market that meets the needs of dermatology patients.'

Thorsten Thormann, Senior Vice President, New Product Discovery at LEO Pharma, said the alliance 'marks our entry into the area of biotherapeutics for dermatology'.

  • Companies:
  • Leo Pharma
  • ArGEN-X
See more

You may also like

Research & Development

arGEN-X awarded €1.5m grant from IWT in Flanders

Read more
To advance the application of NHance Fc modifications in therapeutic antibodies

Trending Articles

  1. Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes
  2. Efficient PFAS-free degassing of aqueous solutions New silicone-based degassing chamber eliminates the risk of PFAS contamination
  3. BioPharmaSpec expands its biopharma discovery and preclinical capabilities with three new facilities The contract research organisation (CRO) has expanded its European presence with three facilities, which are catered for biopharmaceutical drug discovery and preclinical characterisation
  4. CDMO market trends and dynamics The rise of the embedded model
  5. Transmission Raman Spectroscopy - access the webinar series today Offering significant advantages for bulk, quantitative and non-destructive analysis, Transmission Raman Spectroscopy is a preferred choice for applications where surface analysis is insufficient or prone to errors. Speakers from Agilent, Novartis Pharma, AstraZeneca, Bristol-Myers Squibb and AbbVie go deeper in this FREE webinar series

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Research & Development

arGEN-X awarded €1.5m grant from IWT in Flanders

To advance the application of NHance Fc modifications in therapeutic antibodies
Research & Development

Shire signs monoclonal antibody agreement with arGEN-X

Will make an upfront payment to arGEN-X of €15m
Research & Development

arGEN-X to collaborate with Bayer

To discover and develop therapeutic antibody candidates
Research & Development

LEO Pharma and University of Queensland enter skin cancer treatments collaboration

Agreement will cover areas of skin cancer in which LEO Pharma is already active
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Drug approvals: more numerous but niche

After many years of low approval rates, in 2012 more than 30 new drugs were approved by the European Medicines Agency. Although many of them were niche products, some were for diseases with large patient populations, such as diabetes and various forms of cancer
Research & Development

LEO Pharma unveils collaboration strategy for dermatology treatments

To form five long-term partnerships in four countries
Research & Development

Argen-X launches NHance technology

To leverage power of Simple antibody platform to generate better human antibody therapeutics
Subscribe now